Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
Astellas, Tmunity, underscore rocky terrain of CAR-T and gene therapies
Business, CAR-T Therapy, Chimeric Antigen Receptor Natural Killer T Cells (CAR-NKT cells), Clinical Studies, Clinical Trials, Discontinued Clinical Trials, Gene Therapy, Patient Deaths, R&D, R&D, Rare Neuromuscular Diseases, Strategy, Terminated Development, X-Linked Myotubular Myopathy (XLMTM)Deaths associated with Astellas Pharma’s gene therapy program for patients with X-linked Myotubular Myopathy underscore some of the risks of developing potential one-and-done treatment options for serious diseases.
CRISPR Pioneer Caribou Nets $115 Million to Advance Promising Pipeline
Business, CAR-T Therapy, Chimeric Antigen Receptor Natural Killer T Cells (CAR-NKT cells), Clinical Trials, CRISPR, Financing, Gene Editing, Immune Cells, Product Pipeline, R&D, Relapsed/refractory B cell non-Hodgkin lymphoma, Series CCaribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform.
NKarta Therapeutics is using engineered chimeric antigen receptor natural killer T cells (CAR-NKT cells) for allogeneic therapy, showing substantial benefits both in vitro and in vivo, according to the company’s CSO James Trager at the virtual CAR-TCR Summit – Europe.